- Home
- BBIO
BBIO
BridgeBio Pharma Inc.
as 04-18-2025 1:31pm EST
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | N/A | IPO Year: | 2019 |
| Target Price: | $53.00 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.62 - $39.47 | Next Earning Date: | 05-01-2025 |
| Revenue: | $221,902,000 | Revenue Growth: | 2285.27% |
| Revenue Growth (this year): | 14.88% | Revenue Growth (next year): | 121.23% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ellis Andrea | BBIO | Director | Apr 14 '25 | Sell | $35.00 | 10,000 | $350,000.00 | 12,000 | |
| Ellis Andrea | BBIO | Director | Apr 1 '25 | Sell | $34.05 | 30,000 | $1,021,500.00 | 12,000 | |
| Kumar Neil | BBIO | Chief Executive Officer | Mar 25 '25 | Sell | $36.87 | 75,000 | $2,764,942.50 | 4,948,447 | |
| Valantine Hannah | BBIO | Director | Mar 6 '25 | Sell | $32.58 | 12,875 | $419,499.69 | 1,764 | |
| KKR Genetic Disorder L.P. | BBIO | 10% Owner | Mar 5 '25 | Sell | $32.96 | 6,000,000 | $197,760,000.00 | 19,260,971 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 25 '25 | Sell | $33.58 | 75,000 | $2,517,971.14 | 4,948,447 | |
| STEPHENSON BRIAN C | BBIO | CFO and Treasurer | Feb 25 '25 | Sell | $33.68 | 8,500 | $282,114.88 | 102,464 | |
| Kumar Neil | BBIO | Chief Executive Officer | Feb 16 '25 | Sell | $36.35 | 31,543 | $1,140,024.26 | 4,948,447 | |
| STEPHENSON BRIAN C | BBIO | Secretary, Treasurer & CFO | Feb 16 '25 | Sell | $36.16 | 4,148 | $149,973.43 | 102,464 | |
| VIKING GLOBAL INVESTORS LP | BBIO | 10% Owner | Jan 31 '25 | Sell | $34.90 | 3,065,616 | $106,989,998.40 | 22,055,375 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
19 days ago
BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial
GlobeNewswire
19 days ago
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
MT Newswires
19 days ago
Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target
Insider Monkey
21 days ago
Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy
MT Newswires
23 days ago
BridgeBio Pharma Says Beyonttra Approved in Japan to Treat Heart Condition
GlobeNewswire
23 days ago
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
GlobeNewswire
a month ago
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.